MSLN and Miyoshi myopathy: As MSLN is highly expressed in cancer tissue and is low-to-non-existent in normal tissues, targeting it could reduce on-target/off-tumor toxicities; in addition, the high-level expression in the epithelioid MM and its association with tumor progression render MSLN an ideal biomarker and therapeutic target [123,124].